Evidence map›Paper›PMID 41044880›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Ultrathin Multi-Doped Molybdenum Oxide Nanodots as a Tunable Selective Biocatalyst.

Bao Yue Zhang, Farjana Haque, Shwathy Ramesan, Sanjida Afrin, Muhammad Waqas Khan, Haibo Ding, Xin Zhou, Qijie Ma, Jiaru Zhang, Rui Ou and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Ultrathin Multi-Doped Molybdenum Oxide Nanodots as a Tunable Selective Biocatalyst.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Bao Yue ZhangSchool of Engineering, RMIT University, Melbourne, Victoria, 3000, Australia.ORCID https://orcid.org/0000-0003-3906-4645
Farjana HaqueSchool of Engineering, RMIT University, Melbourne, Victoria, 3000, Australia.
Shwathy RamesanSchool of Engineering, RMIT University, Melbourne, Victoria, 3000, Australia.
Sanjida AfrinSchool of Engineering, RMIT University, Melbourne, Victoria, 3000, Australia.
Muhammad Waqas KhanSchool of Science, RMIT University, Melbourne, Victoria, 3000, Australia.
Haibo DingState Key Laboratory of Digital Medical Engineering, School of Biological Science and Medical Engineering, Southeast University, Nanjing, 211189, China.
Xin ZhouState Key Laboratory of Digital Medical Engineering, School of Biological Science and Medical Engineering, Southeast University, Nanjing, 211189, China.
Qijie MaSchool of Engineering, RMIT University, Melbourne, Victoria, 3000, Australia.
Jiaru ZhangSchool of Engineering, RMIT University, Melbourne, Victoria, 3000, Australia.
Rui OuSchool of Engineering, RMIT University, Melbourne, Victoria, 3000, Australia.
Md MohiuddinSchool of Engineering, RMIT University, Melbourne, Victoria, 3000, Australia.
Enamul HaqueSchool of Engineering, RMIT University, Melbourne, Victoria, 3000, Australia.
Yichao WangSchool of Science, RMIT University, Melbourne, Victoria, 3000, Australia.
Azmira JannatSchool of Engineering, RMIT University, Melbourne, Victoria, 3000, Australia.
Yumin LiSchool of Engineering, RMIT University, Melbourne, Victoria, 3000, Australia.
Robi S DattaSchool of Engineering, RMIT University, Melbourne, Victoria, 3000, Australia.
Kate FoxSchool of Engineering, RMIT University, Melbourne, Victoria, 3000, Australia.
Guolang LiDepartment of Computer Science, Information Technology Management, Hong Kong Baptist University, Hong Kong, 999077, China.
Hujun JiaSchool of Microelectronics, Xidian University, Xi'an, 710071, China.
Jian Zhen OuSchool of Engineering, RMIT University, Melbourne, Victoria, 3000, Australia.ORCID https://orcid.org/0000-0002-6971-2634

Funding

Australian Research Council Centre of Excellence in Optical Microcombs for Breakthrough Science CE230100006
6 · The paper itself

Abstract

The reactive oxygen species (ROS) serve a significant role in cancer therapy due to their oxidative capabilities to modulate cellular functions from homeostasis to apoptosis. While conventional noble metal nanoparticles exhibit superior biocatalytic efficacy in ROS induction, their indistinctive toxicity toward cells and organisms limit their potential for targeted cancer therapy. Here, ultrathin biocompatiable molybdenum oxides (MoO

Indexed as

Metal NanoparticlesMolybdenumOxidesBiocatalysisHeLa CellsHumansReactive Oxygen SpeciesMolybdenummolybdenum dioxidemolybdenum oxideOxidesReactive Oxygen Speciesbiocatalystcancer therapycytotoxicitymulti‐doped molybdenum oxidereactive oxygen species

Identifiers

PMID41044880
PMCPMC12591189

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.